Survival outcomes of hypomethylating agents maintenance therapy in new diagnosed AML patients: Real experience data

Basit Öğe Kaydı
dc.contributor.authorKarakuş, Volkan
dc.contributor.authorMaral, Senem
dc.contributor.authorKaya, Egemen
dc.contributor.authorGemici, Aliihsan
dc.contributor.authorDere, Yelda
dc.contributor.authorSevindik, Ömür Gökmen
dc.date.accessioned2023-05-26T08:05:02Z
dc.date.available2023-05-26T08:05:02Z
dc.date.issued2022
dc.departmentALKÜ, Fakülteler, Tıp Fakültesi, Temel Tıp Bilimleri Bölümü
dc.description.abstractOBJECTIVE: Acute myeloid leukemia (AML) is a hematological malignancy that frequently affects elderly population. With introducing the hypomethylating agents (HMAs) in elderly AML treatment, survival rates and quality of life have improved. However, long-term management in elderly and frail patients is still a challenge. In the present study, we aimed to determine whether HMA maintenance therapy is required until disease progression in frail and elderly AML patients by examining with a real-life data. METHODS: In a multicenter study, we analyzed non-promyelocytic elderly AML patients who were treated with first-line azacitidine or decitabine monotherapy in two different groups, retrospectively. While patients were treated with HMA until progression in the maintenance group, 6+3 cycles of azacitidine or decitabine were administered as a standard care of elderly AML patients in the non-maintenance group. Survival outcomes were compared between the groups. RESULTS: HMA therapy was maintained until progression in 20 patients, and HMA therapy was terminated after 6+3 cycles in 21 patients. Patients received a median of 6 (1–14) HMA cycles during follow-up time. The median 7.5 months of overall survival were observed (2–17 months) in maintenance and 3 months (1–13 months) in non-maintenance groups (p=0.001). CONCLUSION: Despite long-term exposure to HMA may appear as a risk factor for complications and toxicities in elderly and frail AML patients, the maintenance of therapy until disease progression provides a significant survival advantage. Therefore, we suggest that HMA therapy should continue until disease progression regardless the sort of HMA.
dc.identifier.citation336
dc.identifier.doi10.14744/nci.2021.42800
dc.identifier.endpage331en_US
dc.identifier.issue9en_US
dc.identifier.startpage4en_US
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/1130076/survival-outcomes-of-hypomethylating-agents-maintenance-therapy-in-new-diagnosed-aml-patients-real-experience-data
dc.identifier.urihttps://hdl.handle.net/20.500.12868/2187
dc.identifier.volume2022en_US
dc.indekslendigikaynakTR-Dizin
dc.language.isoen
dc.relation.ispartofİstanbul Kuzey Klinikleri
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectAcute Myeloid Leukemia
dc.subjectAzacitidine
dc.subjectDecitabine
dc.subjectHypomethylating Agents
dc.titleSurvival outcomes of hypomethylating agents maintenance therapy in new diagnosed AML patients: Real experience data
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
document - 2023-05-25T095721.465.pdf
Boyut:
194.6 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

TR-Dizin İndeksli Yayınlar Koleksiyonu